167 related articles for article (PubMed ID: 37183363)
1. Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages.
Comunanza V; Gigliotti C; Lamba S; Doronzo G; Vallariello E; Martin V; Isella C; Medico E; Bardelli A; Sangiolo D; Di Nicolantonio F; Bussolino F
Mol Oncol; 2023 Aug; 17(8):1474-1491. PubMed ID: 37183363
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
[TBL] [Abstract][Full Text] [Related]
3. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
Roda JM; Sumner LA; Evans R; Phillips GS; Marsh CB; Eubank TD
J Immunol; 2011 Aug; 187(4):1970-6. PubMed ID: 21765015
[TBL] [Abstract][Full Text] [Related]
5. Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes.
Hood JL
Med Hypotheses; 2016 Sep; 94():118-22. PubMed ID: 27515216
[TBL] [Abstract][Full Text] [Related]
6. OncoVEX
Estrada J; Zhan J; Mitchell P; Werner J; Beltran PJ; DeVoss J; Qing J; Cooke KS
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164449
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the treatment-naive immune microenvironment in melanoma with
Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
[TBL] [Abstract][Full Text] [Related]
8. Paracrine regulation of vascular endothelial growth factor--a expression during macrophage-melanoma cell interaction: role of monocyte chemotactic protein-1 and macrophage colony-stimulating factor.
Varney ML; Olsen KJ; Mosley RL; Singh RK
J Interferon Cytokine Res; 2005 Nov; 25(11):674-83. PubMed ID: 16318581
[TBL] [Abstract][Full Text] [Related]
9. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade.
Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA
Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021
[TBL] [Abstract][Full Text] [Related]
10. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
11. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells.
Armstrong CA; Botella R; Galloway TH; Murray N; Kramp JM; Song IS; Ansel JC
Cancer Res; 1996 May; 56(9):2191-8. PubMed ID: 8616871
[TBL] [Abstract][Full Text] [Related]
13. Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanoma.
Hornsteiner F; Vierthaler J; Strandt H; Resag A; Fu Z; Ausserhofer M; Tripp CH; Dieckmann S; Kanduth M; Farrand K; Bregar S; Nemati N; Hermann-Kleiter N; Seretis A; Morla S; Mullins D; Finotello F; Trajanoski Z; Wollmann G; Ronchese F; Schmitz M; Hermans IF; Stoitzner P
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631706
[TBL] [Abstract][Full Text] [Related]
14. Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma.
Kim D; An L; Moon J; Maymi VI; McGurk AI; Rudd BD; Fowell DJ; White AC
Cancer Res; 2023 Jul; 83(14):2328-2344. PubMed ID: 37195124
[TBL] [Abstract][Full Text] [Related]
15. VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.
Comunanza V; Corà D; Orso F; Consonni FM; Middonti E; Di Nicolantonio F; Buzdin A; Sica A; Medico E; Sangiolo D; Taverna D; Bussolino F
EMBO Mol Med; 2017 Feb; 9(2):219-237. PubMed ID: 27974353
[TBL] [Abstract][Full Text] [Related]
16. T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.
Neubert NJ; Schmittnaegel M; Bordry N; Nassiri S; Wald N; Martignier C; Tillé L; Homicsko K; Damsky W; Maby-El Hajjami H; Klaman I; Danenberg E; Ioannidou K; Kandalaft L; Coukos G; Hoves S; Ries CH; Fuertes Marraco SA; Foukas PG; De Palma M; Speiser DE
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643229
[TBL] [Abstract][Full Text] [Related]
17. Global pannexin 1 deletion increases tumor-infiltrating lymphocytes in the BRAF/Pten mouse melanoma model.
Sanchez-Pupo RE; Finch GA; Johnston DE; Craig H; Abdo R; Barr K; Kerfoot S; Dagnino L; Penuela S
Mol Oncol; 2024 Apr; 18(4):969-987. PubMed ID: 38327091
[TBL] [Abstract][Full Text] [Related]
18. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
19. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
20. Local Delivery of OncoVEX
Moesta AK; Cooke K; Piasecki J; Mitchell P; Rottman JB; Fitzgerald K; Zhan J; Yang B; Le T; Belmontes B; Ikotun OF; Merriam K; Glaus C; Ganley K; Cordover DH; Boden AM; Ponce R; Beers C; Beltran PJ
Clin Cancer Res; 2017 Oct; 23(20):6190-6202. PubMed ID: 28706012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
